BF
RIGL icon

BOK Financial’s Rigel Pharmaceuticals RIGL Stock Holding History

BOK Financial’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$599K Buy
15,306
+2,349
+18% +$72.5K 0.01% 526
2026
Q1 		$350K Buy
+12,957
New +$435K 0.01% 605

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOK Financial's RIGL Position: Q2 2026 in Review

BOK Financial increased its Rigel Pharmaceuticals (RIGL) stake by 18% in Q2 2026, buying an estimated $72.5K and bringing the position to 15,306 shares worth $599K. The position accounts for 0.01% of the portfolio, ranked #526.

BOK Financial first reported a position in RIGL in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • BOK Financial held 15,306 shares of Rigel Pharmaceuticals worth $599K as of Q2 2026.
  • BOK Financial bought 2,349 Rigel Pharmaceuticals shares in Q2 2026, an estimated $72.5K.
  • Rigel Pharmaceuticals made up 0.01% of BOK Financial's portfolio in Q2 2026, its #526 holding.
  • BOK Financial first reported a position in Rigel Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.